A High‐Throughput Assay for Monitoring and Quantifying Amyloid‐β Accumulation and Clearance in Alzheimer's Disease Cell Models
Journal of Neurochemistry · 2026-05 · 170 (5)
DOI: 10.1111/jnc.70473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 16.05.2026. Verfasst von Ajish Ariyath und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Sarich and Patricia Neuroscience Research Inst…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, High-Throughput Screening Assays. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, National Foundation for Medical Research and Innovation.
Themen: Demenz
Abstract (Originalsprache)
Amyloidogenic proteins, such as amyloid‐β (Aβ), self‐assemble into cross‐β fibrils whose accumulation is central to Alzheimer's disease (AD). Measuring Aβ aggregation and clearance in living cells remains challenging using current cell‐based assays, which are often low‐throughput or not suited for real‐time monitoring. This study aimed to (1) develop a robust, quantitative, and scalable fluorescence‐based assay using Amytracker to monitor Aβ accumulation and clearance in an Aβ‐producing neuronal cell model, and (2) validate its utility for mechanistic studies and therapeutic screening. We established a plate‐based fluorescence assay using Amytracker in MC65 neuronal AD model expressing the Amyloid precursor protein C‐terminal fragment (APP‐C99) that generates Aβ. Accumulation and clearance of Aβ were quantified by measuring Amytracker fluorescence under basal conditions and after inducing Aβ clearance using a Tet‐suppressible system. We utilized this assay to evaluate cell death inhibitors ferrostatin‐1 and liproxstatin‐1 and proteasome activator IU1. Specificity of the assay for amyloidogenic proteins was assessed by treating wild‐type neuroblastoma cells with Aβ, human islet amyloid polypeptide (hIAPP), or non‐aggregating Aβ controls. Validation included Aβ immunoblotting and cell viability assays. In APP‐C99 expressing cells, elevated Amytracker fluorescence correlated with increased Aβ accumulation and reduced cell viability. Supplementation of ferrostatin‐1, liproxstatin‐1, and IU1, on these cells, markedly reduced Amytracker signal, indicating decreased Aβ burden. Furthermore, the Amytracker assay specifically detected amyloidogenic protein aggregation: wild‐type cells exposed to Aβ42 or hIAPP showed high fluorescence, whereas non‐aggregating Aβ16 peptide did not. The Amytracker assay provides a simple, non‐toxic, and high‐throughput platform for quantifying Aβ accumulation and clearance in live cell models. Its sensitivity, specificity, and compatibility with high‐throughput screening make it a valuable tool for studying Aβ dynamics, interrogating mechanisms of proteostasis, and identifying therapeutic candidates targeting Aβ. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Sarich and Patricia Neuroscience Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
- Alzheimer's Research Australia, Nedlands, Western Australia, Australia.
- University of Western Australia Medical School, Perth, Western Australia, Australia.
- School of Biomedical Science, Macquarie University, Sydney, New South Wales, Australia.
- Curtin Medical School, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Western Australia, Australia.
ORCID-Profile: W M A D Binosha Fernando, Prashant Bharadwaj
Förderung
- National Health and Medical Research Council
- National Foundation for Medical Research and Innovation
Zitieren
APA
Ariyath, A., Arigo, F. D., Fyfe, A., Fernando, W. M. A. D. B., Martins, R., & Bharadwaj, P. (2026). A High‐Throughput Assay for Monitoring and Quantifying Amyloid‐β Accumulation and Clearance in Alzheimer's Disease Cell Models. Journal of Neurochemistry, 170(5). https://doi.org/10.1111/jnc.70473
Vancouver
Ariyath A, Arigo FD, Fyfe A, Fernando WMADB, Martins R, Bharadwaj P. A High‐Throughput Assay for Monitoring and Quantifying Amyloid‐β Accumulation and Clearance in Alzheimer's Disease Cell Models. Journal of Neurochemistry. 2026;170(5). doi:10.1111/jnc.70473
BibTeX
@article{Ariyath2026,
author = {Ariyath, Ajish and Arigo, Fraulein Denise and Fyfe, Anna and Fernando, W M A D Binosha and Martins, Ralph and Bharadwaj, Prashant},
title = {A High‐Throughput Assay for Monitoring and Quantifying Amyloid‐β Accumulation and Clearance in Alzheimer's Disease Cell Models},
journal = {Journal of Neurochemistry},
year = {2026},
volume = {170},
number = {5},
doi = {10.1111/jnc.70473}
}
EUVIMED